Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endocare and Galil Medical sign merger agreement
The terms of the agreement call for a stock-for-stock merger transaction resulting in Galil Medical becoming a wholly-owned subsidiary of Endocare, and would provide current Endocare stockholders 52%,
The terms of the agreement call for a stock-for-stock merger transaction resulting in Galil Medical becoming a wholly-owned subsidiary of Endocare, and would provide current Endocare stockholders 52%,
This agreement guarantees Kamada a steady supply of raw material that meets the international standards set by the FDA and European Medicines Agency. The suppliers are also required
ArQule and Daiichi Sankyo have entered into a binding letter of intent for an exclusive license, co-development and co-commercialization agreement under which they shall collaborate to conduct research,
New investor, Longitude Venture Partners led the round and was joined by existing investors Adams Capital Management, Quaker BioVentures, Birchmere Ventures, Techno Venture Management, and Draper Triangle Ventures.
According to the company, DiaVis delivers a blend of key antioxidants, including Pycnogenol, and other nutrients found to play a role in helping to combat oxidative stress and
For the first time, European hospitals will have access to a reliable, rapid test for Clostridium difficile, which simultaneously detects and identifies the commonly occurring strains and specifically
Under the service agreement, Stem Cell Sciences (SCS) will create standard culture conditions for CHDI’s mouse embryonic stem (ES) cell lines using its serum-free and feeder-free Esgro Complete
Simultaneous with the financial closing, Psyadon and Schering executed an agreement under which Psyadon will acquire worldwide rights to Schering’s selective dopamine D1 receptor antagonist, ecopipam. The new
The Phase I/II study was designed to first evaluate a dose of MKC-1 to be used safely in combination with pemetrexed (Alimta) to treat patients with advanced non-small
The company has also announced that Gary Tollefson, current CEO and president, is taking a leave of absence from the company. Dr Tollefson is expected to remain a